Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibiotic Prophylaxis for TIVAD Insertion
NCT05304871Withdrawn
- Sponsor
- Dartmouth Health
- Start
- Jan 2024
- Primary completion
- Mar 2027
- Modality
- Reversible Covalent Inhibitors
01
Overview
Randomised, double-blind trial of cefazolin in surgical site infection (SSI) and catheter-related bloodstream infection (CRBSI) (2 arms), sponsored by Dartmouth Health. Primary endpoints: Surgical Site Infection at 30 days and Central Line Associated Blood Stream Infection at 30 days. Planned start Jan 2024; status: withdrawn.
02
Drugs
cefazolin
03
Conditions
surgical site infection (SSI)catheter-related bloodstream infection (CRBSI)
Beyond the preview
Go deeper on NCT05304871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05304871.